Browse the corpus

High-altitude cerebral edema (HACE) is a severe, potentially fatal neurologic disorder resulting from rapid ascent to high altitude, typically above 2,500 m. The condition represents the advanced stage of acute mountain sickness and arises from hypoxia-induced cerebral vasodilation, increased capillary permeability, and subsequent vasogenic edema. Risk factors include rapid ascent, inadequate acclimatization, prior altitude illness, and sustained physical exertion. Clinical manifestations include severe headache, ataxia, confusion, fatigue, and progressive alteration in mental status, which may advance to coma and death within 12 to 24 hours due to brain herniation. Diagnosis is primarily clinical, supported by a history of recent altitude exposure and characteristic neurologic findings. Immediate descent remains the cornerstone of management, often combined with supplemental oxygen and dexamethasone administration to reduce cerebral edema. Delays in intervention increase the risk of fatality, which may reach 50% without treatment. Most patients achieve complete neurologic recovery following timely descent and supportive therapy. Prognosis depends on early recognition and rapid initiation of management. This activity for healthcare professionals is designed to sharpen learners' skills in evaluating and managing HACE. Participants will gain deeper insights into the condition's etiology, risk factors, pathophysiology, clinical presentation, and evidence-based diagnostic and therapeutic recommendations. Advanced proficiency will empower clinicians to collaborate with interprofessional teams providing care for individuals with HACE. Objectives: Differentiate high-altitude cerebral edema from acute mountain sickness based on clinical and diagnostic features. Implement personalized, evidence-based strategies for managing high-altitude cerebral edema and mitigating its possible sequelae. Improve patient understanding of preventive measures, symptom recognition, and emergency responses necessary to reduce high-altitude cerebral edema-related morbidity and mortality. Apply effective methods to optimize care coordination among interprofessional team members to improve outcomes for patients experiencing high-altitude cerebral edema. Access free multiple choice questions on this topic.

Each year, more than 200 million individuals travel to high-altitude regions, a number that continues to rise as these areas become more accessible.[1] "High altitude" is defined as elevations exceeding 1,500 m, although high-altitude illnesses (HAIs) rarely occur below 2,500 m. At these elevations, the reduced partial pressure of oxygen produces a range of pathophysiologic effects.[2] Neurologic manifestations of altitude illness exist along a continuum, from the relatively mild high-altitude headache to the more common acute mountain sickness (AMS), and ultimately to the severe and potentially fatal high-altitude cerebral edema (HACE). HACE is characterized by ataxia, fatigue, and progressive alteration in mental status. The condition is regarded as the terminal or most severe form of AMS and is the least common altitude-related disorder.[3][4] Compared with other altitude illnesses, HACE most often develops above 4,000 m and carries a high mortality risk if not rapidly identified and treated.[5] Management requires immediate descent and supplemental oxygen administration, with evacuation and portable hyperbaric chamber therapy as indicated. Given the growing popularity of high-altitude travel, healthcare professionals must provide patient education on preventive measures, symptom recognition, and timely response to altitude illness.

At elevations exceeding 1,500 m, the reduced partial pressure of inspired oxygen (PIO2) produces physiologic alterations responsible for the spectrum of HAIs. The corresponding linear decline in arterial oxygen partial pressure (PaO2) and arterial oxygen saturation initiates compensatory mechanisms that promote acclimatization. An immediate response is an increase in minute ventilation, observed within minutes of exposure to the reduced PIO2 and PaO2. This hyperventilation decreases arterial carbon dioxide (PaCO2), thereby raising PaO2 levels.[6] The resulting hypocapnia causes respiratory alkalosis, which the kidneys gradually correct over the course of 1 to 2 days by excreting bicarbonate. These ventilatory and metabolic adaptations commence shortly after ascent and reach maximal effect after approximately 4 to 7 days at a constant altitude. During sleep, many individuals exhibit periodic breathing patterns, characterized by alternating hyperpnea and apnea, which may contribute to symptom development and progression of AMS and HACE.[7] The brain is among the most sensitive organs to hypoxia and oxidative stress. Consequently, the cerebral manifestations of HAI reflect the effects of hypoxic injury on the central nervous system.[8][9] High-altitude headache, AMS, and HACE form a continuum of neurologic altitude disorders that improve with supplemental oxygen and descent. Cerebral blood flow and oxygen delivery depend on the balance between hypoxia-induced vasodilation and hypocapnia-induced vasoconstriction. Hypoxia-driven cerebral vasodilation predominates during initial exposure. Following an acute reduction in PaO2, such as after rapid ascent, cerebral blood flow may increase by approximately 24% within hours. Over the next several days, sustained hyperventilation lowers PaCO2, promoting vasoconstriction and a return of cerebral blood flow toward baseline values. This balance is critical to maintaining cerebral homeostasis. Cerebral oxygenation may fall when hypocapnia-induced vasoconstriction predominates. Conversely, when hypoxic vasodilation prevails, excessive perfusion and capillary leakage can increase the risk of cerebral edema.[10]

Cerebral blood flow and oxygen delivery depend on the balance between hypoxia-induced vasodilation and hypocapnia-induced vasoconstriction. Hypoxia-driven cerebral vasodilation predominates during initial exposure. Following an acute reduction in PaO2, such as after rapid ascent, cerebral blood flow may increase by approximately 24% within hours. Over the next several days, sustained hyperventilation lowers PaCO2, promoting vasoconstriction and a return of cerebral blood flow toward baseline values. This balance is critical to maintaining cerebral homeostasis. Cerebral oxygenation may fall when hypocapnia-induced vasoconstriction predominates. Conversely, when hypoxic vasodilation prevails, excessive perfusion and capillary leakage can increase the risk of cerebral edema.[10] The likelihood of developing HAI is primarily determined by the rate of ascent and the maximum altitude reached. Adequate acclimatization to hypobaric hypoxia significantly decreases disease incidence, and insufficient acclimatization is a principal contributing factor. A distinguishing feature of altitude illness is its onset during the early phase of ascent, differentiating it from other neurologic or systemic conditions. Epidemiologic studies demonstrate a positive correlation between rapid ascent and the occurrence of altitude-related disorders. In HACE, symptoms typically appear within 1 to 2 days after ascent. Most patients initially experience AMS before progression to HACE, although isolated cases of HACE without preceding AMS have been documented, particularly in association with high-altitude pulmonary edema (HAPE). HACE is uncommon below 3,500 m and most frequently occurs above 4,000 m. Changes in sleeping altitude represent a major risk determinant. Current guidelines recommend gradual ascent, with sleeping elevation increases limited to no more than 500 m per day above 3,000 m, and the inclusion of rest days without further elevation gain every 2 to 4 days.[11] A staged ascent to 3,000 m with an intermediate overnight stay around 1,500 m further reduces HACE incidence. Additional risk reduction may be achieved by spending several days to a week at approximately 3,000 m before continued ascent. The risk of AMS and HACE is greatly increased when these guidelines are not followed and proper acclimatization is not achieved.[12]

HACE affects approximately 0.5% to 1% of travelers ascending to altitudes between 4,000 and 5,000 m.[13] Other altitude-related disorders, including AMS and HAPE, may occur at lower elevations, whereas HACE is uncommon below 3,500 m. HACE frequently coexists with HAPE when diagnosed at such elevations. Although precise incidence data are likely underestimated, studies indicate that 13% to 20% of patients with HAPE also develop concurrent HACE. Furthermore, autopsy findings consistent with HACE have been reported in approximately 50% of individuals who died from HAPE. Substantial clinical overlap exists between severe AMS and HACE, complicating diagnostic accuracy and epidemiologic reporting. This overlap underscores the continuum of HAIs and the difficulty in delineating distinct diagnostic boundaries among these entities.[14] AMS precedes nearly all cases of HACE, and failure to recognize or respond to AMS symptoms while continuing ascent constitutes a major risk factor for HACE development. Rapid ascent in unacclimatized individuals markedly increases disease risk, whereas adherence to gradual and controlled ascent protocols substantially reduces incidence. Daily increases exceeding 500 m in sleeping altitude, excessive physical exertion, and abrupt altitude gain are well-established risk factors. HACE occurs across all ages and sexes but is reported more frequently in individuals younger than 50 years. No meaningful differences in incidence have been observed between pediatric and adult groups or between sexes. Smoking and common comorbidities appear to have minimal influence on susceptibility, although individuals with a history of migraine headaches exhibit increased vulnerability to AMS and subsequent progression to HACE.[15][16] A prior episode of HAI significantly elevates recurrence risk during future ascents under similar conditions. Genetic or physiologic predisposition may contribute to this heightened susceptibility. Travelers with a history of HACE should undertake gradual ascent schedules with careful monitoring for recurrent symptoms.[17]

As detailed under Etiology, hypoxemia is the principal mechanism driving the physiologic alterations underlying HAI. HACE develops as a consequence of hypobaric hypoxia that induces cerebral vascular changes, resulting in capillary leakage, cerebral edema, and elevation of intracranial pressure (ICP). The ensuing ICP rise produces progressive neurologic impairment, coma, and death. The pathophysiologic process of HACE represents a continuum of the mechanisms observed in AMS, highlighting the shared progression among altitude-related disorders.[18] Multiple neurohormonal and inflammatory mediators contribute to cerebral vasodilation, overperfusion, and capillary permeability, including vascular endothelial growth factor, nitric oxide, bradykinin, reactive cytokines, and free radicals.[19] Disruption of the cerebral microvasculature leads primarily to vasogenic edema, although cytotoxic edema may occur in advanced stages.[20] The resulting increase in ICP compromises cerebral perfusion, producing cellular ischemia and neurologic deterioration. Progressive intracranial hypertension can cause compression of extraaxial structures, focal neurologic deficits, decreased consciousness, and, ultimately, brainstem herniation and death. The “tight-fit” hypothesis proposes that individuals with smaller ventricles or reduced intracranial CSF compliance experience greater ICP elevations and more severe HACE manifestations.[21] This concept supports clinical observations that older adults, who typically exhibit cerebral volume loss, demonstrate lower susceptibility compared with younger individuals.

The initial diagnosis of HACE is clinical, established through a history of recent ascent to high altitude with characteristic neurologic symptoms. Most patients present with preceding AMS symptoms, including headache, fatigue, dizziness, anorexia, and nausea or vomiting. Clinical findings typically manifest at altitudes above 4,000 m in unacclimatized individuals who have undergone rapid ascent from lower elevations within the preceding days. The hallmark features of HACE are altered mental status and ataxia. Often subtle, ataxia is the earliest and most specific clinical sign. The cerebellum demonstrates particular vulnerability to edema, resulting in early cerebellar manifestations such as impaired fine motor control, loss of coordination, and unsteady gait. With progression, patients develop worsening mental status and motor dysfunction, which may advance to decreased consciousness, coma, and death. Although uncommon, focal neurologic deficits such as isolated cranial nerve palsies have been reported.[22] Seizures may occur. Marked lassitude is frequently observed, with an inability to perform basic self-care or self-rescue even in early stages of HACE. Ataxia is the most specific physical examination finding suggestive of HACE. Gait assessment may reveal difficulty with heel-to-toe walking, a broad-based or shuffling gait, and frequent stumbling. Any patient at altitude who exhibits ataxia should be presumed to have HACE until proven otherwise. Focal neurologic deficits are uncommon but have been documented in some cases.[23] Extraaxial compression secondary to cerebral edema in HACE has been reported to produce isolated cranial nerve palsies.[24] A comprehensive neurologic examination is indicated in all patients with suspected HACE, although the presence of focal findings in the absence of ataxia should prompt consideration of alternative neurologic diagnoses.

No validated clinical decision scores or diagnostic criteria are specific to HACE. The diagnosis is clinical, based on a compatible history of recent ascent and characteristic symptoms. Laboratory testing and neuroimaging are not required to establish the diagnosis, and treatment should not be delayed for additional evaluation if HACE is suspected. The typical clinical picture involves ataxia and encephalopathy following ascent to high altitude. A prior history of AMS is frequently reported when available. The development of neurologic findings, such as progressive cognitive decline, decreased level of consciousness, impaired coordination, slurred speech, or lassitude, indicates progression from AMS to HACE. No laboratory test is specific or sensitive for HACE. Laboratory evaluation may assist in excluding metabolic derangements or alternative causes of encephalopathy but cannot confirm the diagnosis. Neuroimaging is not required to diagnose HACE. When performed, magnetic resonance imaging (MRI) is the preferred modality, as computed tomography (CT) findings are often normal. MRI typically demonstrates white matter signal changes consistent with reversible edema, which may resolve on follow-up imaging. In some cases, these abnormalities persist for several weeks after presentation.[25] No direct correlation exists between the radiographic severity of edema and clinical outcome. MRI findings should not be used to predict prognosis.[26] When a lumbar puncture is performed to exclude other causes of encephalopathy, CSF analysis may demonstrate a mildly elevated opening pressure with otherwise normal findings in patients with HACE.[27] The normal biochemical profile of the CSF underscores this condition's noninflammatory, hypoxia-driven mechanism.

Prompt descent is mandatory if HACE is suspected, regardless of symptom severity. Descent is the most effective and definitive treatment, with a reduction of 300 to 1,000 m often resulting in marked clinical improvement. Adjunctive interventions are supportive and should never delay or replace descent. Since hypoxia drives the underlying pathophysiology of HACE, supplemental oxygen therapy targeting an SpO2 greater than 90% should be administered along with or in place of descent when immediate evacuation is not possible. If available, portable hyperbaric oxygen therapy may also be employed during or while awaiting descent. Pharmacologic management is secondary and serves as an adjunct when descent is delayed. Dexamethasone is the preferred agent, given as an 8-mg loading dose followed by 4 mg every 6 hours until descent is achieved and symptoms resolve. Administration may be intravenous, oral, or intramuscular.[28] Pediatric dosing is 0.15 mg/kg every 6 hours. Acetazolamide has no therapeutic role in HACE. Since most cases of HACE evolve from AMS, preventive strategies are similar: staged ascent, controlled daily increases in sleeping altitude, and prophylactic use of acetazolamide or dexamethasone.[29] Increases in sleeping elevation should not exceed 500 m per day above 3,000 m. A staged ascent to 3,000 m with several days of acclimatization before further elevation reduces the risk of both AMS and HACE. Above this altitude, rest days every 3 to 4 days or after every 1,000 m of gain are recommended.

The differential diagnosis for HACE is extensive and encompasses numerous neurologic and metabolic disorders. Most alternative diagnoses require evacuation to a lower altitude and transfer to a higher level of care for comprehensive evaluation. Untreated HACE carries a high mortality rate. Consequently, any patient in whom the condition is suspected should undergo immediate evacuation. HACE may be mistaken for the less severe AMS. Failure to identify the progression of AMS, particularly when early cerebellar findings such as subtle ataxia or encephalopathy are present, can delay diagnosis and result in clinical deterioration. Early recognition of ataxia is critical to initiate prompt descent and adjunctive therapy. Intracranial hemorrhage and cerebrovascular accident can closely resemble HACE, presenting with decreased consciousness, ataxia, encephalopathy, or focal neurologic deficits. A focal deficit without other findings should raise concern for these vascular etiologies. However, focal abnormalities, such as isolated cranial nerve palsies, secondary to HACE have been documented.[30] Intracranial mass lesions may produce similar symptoms but typically demonstrate a more gradual onset. Any patient exhibiting these findings at altitude should be presumed to have HACE and evacuated urgently until an alternative diagnosis is confirmed. Abnormal fluid or electrolyte imbalances can resemble HACE. Hyponatremia may produce similar neurologic manifestations and requires laboratory confirmation, although a history of excessive free water intake may be suggestive. Metabolic disturbances, including hypoglycemia, hyperglycemia with diabetic ketoacidosis or hyperosmolar hyperglycemic state, can also mimic the encephalopathy and decreased consciousness characteristic of HACE. Hypercalcemia may present with comparable alterations in mental status. Renal failure with uremia and hepatic failure with hepatic encephalopathy should likewise be considered in patients exhibiting altered mental status at altitude. Infectious causes must remain within the differential diagnosis for encephalopathy at altitude, particularly central nervous system infections such as meningitis or encephalitis. Fever and examination findings, including nuchal rigidity or a positive Kernig or Brudzinski sign, may aid in distinguishing these conditions from HACE.

Infectious causes must remain within the differential diagnosis for encephalopathy at altitude, particularly central nervous system infections such as meningitis or encephalitis. Fever and examination findings, including nuchal rigidity or a positive Kernig or Brudzinski sign, may aid in distinguishing these conditions from HACE. Although HACE can present with seizures, distinguishing it from epilepsy can be challenging, as the postictal phase may include transient confusion and impaired cognition. HACE should be considered less likely in patients with a known history of epilepsy who experience a seizure without preceding AMS symptoms and subsequently return to baseline. Conversely, a new-onset seizure at high altitude raises concern for possible HACE or another serious intracranial process and warrants prompt evacuation for definitive evaluation. Carbon monoxide exposure, such as from camp stoves used in enclosed spaces, should also be considered in patients presenting with altered mental status under these conditions. Intoxication from alcohol or illicit substances, as well as acute psychiatric episodes, remain diagnoses of exclusion when evaluating potential HACE. Improvement in symptoms following descent supports a diagnosis of HACE rather than these alternative etiologies.

Prognosis in HACE is largely determined by symptom severity and the timeliness of descent, highlighting the critical role of early recognition by the healthcare team. Most patients recover fully without lasting neurologic impairment when symptoms are identified promptly, and descent is initiated without delay. If immediate descent is not feasible, adjunctive measures such as supplemental oxygen, portable hyperbaric therapy, or dexamethasone administration may alleviate symptoms and limit progression. Prolonged encephalopathy or delayed descent increases the risk of complications, including coma, seizures, and death. Timely recognition and rapid descent remain the most decisive factors influencing outcomes in HACE.

Failure to recognize HACE or delays in initiating appropriate treatment are associated with markedly increased mortality. The condition can progress rapidly, with mild symptoms advancing to decreased consciousness, coma, seizures, and brain herniation within 24 hours. Patients who do not receive prompt recognition and intervention are at higher risk for long-term neurologic complications. Although uncommon among survivors of severe HACE, persistent neurocognitive deficits involving memory, attention, and executive function may occur. Individuals with residual deficits have demonstrated improvement with targeted neurorehabilitation.

Patient education is essential in reducing the incidence and mortality associated with HAI. Clinicians should be well-versed in established guidelines for gradual ascent and acclimatization and emphasize these principles during pretravel counseling. Individuals traveling to high-altitude environments should receive education regarding the early manifestations of HACE and the critical importance of immediate descent if symptoms occur. Counseling should also address preventive measures for all forms of HAI, including adequate hydration, rest, and staged ascent. Comprehensive patient instruction enables informed decision-making and promotes risk reduction in settings where access to medical care or evacuation resources may be limited.

With the growing number of travelers to high-altitude regions, interprofessional collaboration is essential in the prevention and management of HAI. Preventive strategies should be implemented before travel, with physicians, advanced practice providers, nurses, and wilderness medicine specialists providing education through primary care, travel medicine clinics, and expedition-focused medical organizations. Pharmacists also play a role by advising on appropriate prophylaxis and pharmacologic interventions. During high-altitude expeditions, healthcare teams may include nontraditional members such as local guides, whose field experience may compensate for limited formal medical training. Clear communication and coordinated action among all team members are critical, as early recognition and intervention substantially reduce morbidity and mortality. Integrating preventive counseling, interprofessional collaboration, and a focus on patient safety strengthens health outcomes and optimizes care delivery in remote, resource-limited environments.